A newly introduced acquisition might have a big effect on how medical trials are carried out, notably in group oncology settings. Paradigm Well being, a comparatively younger firm based in 2021, is buying Flatiron Well being’s medical analysis enterprise, which incorporates an intensive tech-enabled U.S. oncology analysis community and a collection of medical analysis options.
Flatiron has constructed up an oncology-focused EHR community and a de-identified database with greater than 4 million affected person data. Greater than 1,000 analysis publications have used its EHR-derived real-world knowledge.
By means of this transaction for an undisclosed sum, Paradigm Well being will increase its community to incorporate greater than 25 tutorial medical facilities and well being methods, in addition to entry to almost 100 group oncology practices nationwide, reaching over 2.4 million sufferers throughout the US.
Paradigm, which was incubated by ARCH Enterprise Companions to deal with inequities in affected person entry to medical analysis, describes this as an acquisition but additionally as a multi-year collaboration between the 2 organizations to maximise the advantages for suppliers, sponsors, and sufferers. It mentioned the long-term collaboration will combine Flatiron’s established medical analysis options and website community with Paradigm Well being’s end-to-end know-how platform, enabling extra sufferers to entry medical trials, with out including expensive infrastructure.
Paradigm’s AI-enabled infrastructure automates affected person matching and website feasibility, and has helped well being methods accrue to trials 4 occasions sooner whereas decreasing supplier burden and accelerating timelines for biopharma sponsors. Paradigm Well being additionally just lately launched a Trial Design Service to allow sponsors to design and execute interventional and pragmatic trials embedded straight into routine care.
The 2 organizations will work to combine Paradigm Well being’s options into Flatiron’s OncoEMR and deploy new capabilities. OncoEMR is an digital well being file for group oncology. Over 4,500 suppliers throughout the Flatiron community of 1,000 community-based most cancers care places use OncoEMR for affected person care and follow operations.
Based in 2012, Flatiron is an unbiased affiliate of the Roche Group. It collaborates with companions in tutorial establishments, coverage teams, regulators, and biopharmaceutical firms. In November 2024, Healthcare Innovation interviewed Neal Meropol, MD, Flatiron’s vp of analysis oncology.
Paradigm Well being will present medical analysis assist to all Flatiron Well being OncoEMR prospects and Flatiron’s present medical analysis companion tutorial medical facilities and well being methods.
“This partnership brings collectively the strengths of each organizations,” mentioned Nathan Hubbard, Flatiron Well being CEO, in a press release. “By combining Paradigm Well being’s AI-powered trial infrastructure with Flatiron’s trusted community and assist throughout tutorial and group oncology websites, we’re constructing a stronger, extra related ecosystem for medical analysis – increasing capabilities, accelerating impression and advancing our shared mission to convey new therapies to sufferers sooner.”
Paradigm mentioned the transaction additionally strengthens its relationships with the biopharma trade. The mixed community permits Paradigm Well being to serve 15 of the highest 20 world biopharma firms and provides capability to run pragmatically designed Part IV medical trials embedded into routine care, growing the velocity of post-market approval proof era.
Paradigm Well being additionally introduced an oversubscribed $78 million Sequence B financing. The spherical was led by ARCH Enterprise Companions, with participation from new investor DFJ Development and present buyers F-Prime, Common Catalyst, GV, Lux Capital, Mubadala Capital, the American Most cancers Society’s BrightEdge Fund, and others.
